

## SUMMARY OF CONFIRMED INFECTIONS

Sanjib Bhattacharyya, PhD  
Laboratory Director

February 2019

Trivikram Dasu, PhD, D(ABMLI)  
Deputy Laboratory Director

### Syphilis

Test	Total	Test	Total
EIA Reactive	52	Darkfield Reactive	0
VDRL Reactive	25	TP-PA Reactive	11

### New Cases of Syphilis

Stage	Number of Cases	
	February 2019	February 2018
Primary syphilis	0	0
Secondary syphilis	0	0
Early latent	0	0
Late latent	1	1
Total	1	1

Source: Wisconsin Division of Health

### HIV

Test	Total	Reactive	Percent (%)
EIA-HIV Ag/Ab combo	298	5	1.7

### *Chlamydia trachomatis* (CT), *Neisseria gonorrhoeae* (GC), and *Trichomonas vaginalis* (Trich) Nucleic Acid Amplification

Source	CT			GC			Trich		
	Tested	Positives	Percent (%)	Tested	Positives	Percent (%)	Tested	Positives	Percent (%)
Urine	475	53	11.2	475	36	7.6	319	20	6.3
Throat	392	15	3.8	481	24	5.0			
Rectal	172	22	12.8	170	9	5.3			
Vaginal			N/A			N/A	56	9	16.1

## Gonorrhea Antimicrobial Susceptibility Testing

Number Tested	Non-Susceptible (NS) / Decreased-Susceptible (DS) Antibiotics			
	Cefixime	Ceftriaxone	Azithromycin	Gentamicin*
50	0	0	4	0

\*No CLSI interpretation available

## Clinical cultures of interest

Source	Identification	Number
Cervix	<i>Neisseria meningitidis</i>	1
Rectum	<i>Neisseria meningitidis</i>	1
Urethra	<i>Neisseria meningitidis</i>	5
Throat	<i>Moraxella catarrhalis</i> ( <i>Branhamella catarrhalis</i> )	3

## Reference cultures

Source	Identification	Number
Respiratory	<i>Actinomyces meyeri</i> *	1
Picc line	<i>Bacillus circulans</i> *	1
Stool	<i>Bacillus licheniformis</i> *	1
Lung	<i>Blastomyces dermatitidis</i> *	1
Bronch wash	<i>Candida glabrata</i> *	1
Blood	<i>Candida glabrata</i> *	1
Wound	<i>Corynebacterium amycolatum</i> *	1
Hip	<i>Corynebacterium pseudodiphtheriticum</i> *	1
Blood	<i>Moraxella osloensis</i> *	1
Blood	<i>Salmonella</i> (Group D1) <i>Enteritidis</i>	1

\*The MHD laboratory targets the 16S rRNA (bacterial) and the D2 region of the 28S rRNA (fungal) genes for sequence-based microbial identification of selective reference isolates.


## Molecular Amplification

Agent	Method	Tested	Positives	Percent (%)
Herpes simplex virus	Real time PCR	36	2	5
Mumps virus	Real time RT-PCR	4	0	0
Norovirus	Real time RT-PCR	1	0	0
Varicella zoster	Real time PCR	1	0	0

**Respiratory Pathogens Surveillance:**

Respiratory Pathogen Panel Test Results		
Virus	Positives	Percent (%)
Human metapneumovirus	7	23.3
Entero/Rhinovirus	5	16.7
Parainfluenza virus type 2	0	0
Parainfluenza virus type 3	0	0
Bocavirus	0	0

Specimens tested: n = 30 (Feb 2019)



**Note:** The MHDL provides comprehensive detection of multiple respiratory viruses and their subtypes: Influenza A, Influenza B, Respiratory Syncytial Virus (RSV), Human Metapneumovirus (hMPV), Enterovirus/ Rhinovirus (ENT/HRV), Adenovirus, Parainfluenza (HPIV 1-4), Coronavirus and Boca viruses. The bacterial targets include *Chlamydia pneumoniae*, *Mycoplasma pneumoniae*, and *Legionella pneumophila*